Literature DB >> 27180074

On a path to accelerate access to Ebola vaccines: The WHO's research and development efforts during the 2014-2016 Ebola epidemic in West Africa.

Ana Maria Henao-Restrepo1, Marie-Pierre Preziosi1, David Wood2, Vasee Moorthy1, Marie Paule Kieny3.   

Abstract

During 2014 and 2015 an outbreak of Ebola deemed a Public Health Emergency of International Concern affected a number of West African countries. The outbreak underscored the need for a vaccine against Ebola. An unprecedented and to great extent collaborative effort built on the availability of a number of candidate vaccines that could enter into clinical phase evaluation. A series of international consultations and activities were led by WHO as a contribution to the unprecedented global efforts to develop and assess an Ebola vaccine. WHO consulted widely, and immediately fostered interactions with the international scientific, ethics, regulatory, vaccine development, public health partners, industry and funders' communities and participated in consortia to facilitate Ebola vaccine assessments. WHO also fostered key activities to ensure the optimal policy and deployment of Ebola vaccines, if licensed. WHO has convened a broad global coalition of experts to develop a Blueprint and a platform for accelerated R&D, in order to avert full-blown epidemics.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27180074      PMCID: PMC5524177          DOI: 10.1016/j.coviro.2016.03.008

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  9 in total

1.  Meeting of the Strategic Advisory Group of Experts on immunization, October 2015 – conclusions and recommendations.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2015-12-11

2.  Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.

Authors:  Selidji T Agnandji; Angela Huttner; Madeleine E Zinser; Patricia Njuguna; Christine Dahlke; José F Fernandes; Sabine Yerly; Julie-Anne Dayer; Verena Kraehling; Rahel Kasonta; Akim A Adegnika; Marcus Altfeld; Floriane Auderset; Emmanuel B Bache; Nadine Biedenkopf; Saskia Borregaard; Jessica S Brosnahan; Rebekah Burrow; Christophe Combescure; Jules Desmeules; Markus Eickmann; Sarah K Fehling; Axel Finckh; Ana Rita Goncalves; Martin P Grobusch; Jay Hooper; Alen Jambrecina; Anita L Kabwende; Gürkan Kaya; Domtila Kimani; Bertrand Lell; Barbara Lemaître; Ansgar W Lohse; Marguerite Massinga-Loembe; Alain Matthey; Benjamin Mordmüller; Anne Nolting; Caroline Ogwang; Michael Ramharter; Jonas Schmidt-Chanasit; Stefan Schmiedel; Peter Silvera; Felix R Stahl; Henry M Staines; Thomas Strecker; Hans C Stubbe; Benjamin Tsofa; Sherif Zaki; Patricia Fast; Vasee Moorthy; Laurent Kaiser; Sanjeev Krishna; Stephan Becker; Marie-Paule Kieny; Philip Bejon; Peter G Kremsner; Marylyn M Addo; Claire-Anne Siegrist
Journal:  N Engl J Med       Date:  2015-04-01       Impact factor: 91.245

3.  A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

Authors:  Jason A Regules; John H Beigel; Kristopher M Paolino; Jocelyn Voell; Amy R Castellano; Zonghui Hu; Paula Muñoz; James E Moon; Richard C Ruck; Jason W Bennett; Patrick S Twomey; Ramiro L Gutiérrez; Shon A Remich; Holly R Hack; Meagan L Wisniewski; Matthew D Josleyn; Steven A Kwilas; Nicole Van Deusen; Olivier Tshiani Mbaya; Yan Zhou; Daphne A Stanley; Wang Jing; Kirsten S Smith; Meng Shi; Julie E Ledgerwood; Barney S Graham; Nancy J Sullivan; Linda L Jagodzinski; Sheila A Peel; Judie B Alimonti; Jay W Hooper; Peter M Silvera; Brian K Martin; Thomas P Monath; W Jay Ramsey; Charles J Link; H Clifford Lane; Nelson L Michael; Richard T Davey; Stephen J Thomas
Journal:  N Engl J Med       Date:  2015-04-01       Impact factor: 91.245

4.  Meeting of the Strategic Advisory Group of Experts on immunization, April 2015: conclusions and recommendations.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2015-05-29

5.  Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.

Authors:  Ana Maria Henao-Restrepo; Ira M Longini; Matthias Egger; Natalie E Dean; W John Edmunds; Anton Camacho; Miles W Carroll; Moussa Doumbia; Bertrand Draguez; Sophie Duraffour; Godwin Enwere; Rebecca Grais; Stephan Gunther; Stefanie Hossmann; Mandy Kader Kondé; Souleymane Kone; Eeva Kuisma; Myron M Levine; Sema Mandal; Gunnstein Norheim; Ximena Riveros; Aboubacar Soumah; Sven Trelle; Andrea S Vicari; Conall H Watson; Sakoba Kéïta; Marie Paule Kieny; John-Arne Røttingen
Journal:  Lancet       Date:  2015-08-03       Impact factor: 79.321

6.  Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges.

Authors:  Stephen B Kennedy; James D Neaton; H Clifford Lane; Mark W S Kieh; Moses B F Massaquoi; Nancy A Touchette; Martha C Nason; Dean A Follmann; Fatorma K Boley; Melvin P Johnson; Gregg Larson; Francis N Kateh; Tolbert G Nyenswah
Journal:  Clin Trials       Date:  2016-01-14       Impact factor: 2.486

7.  Ebola vaccine--an urgent international priority.

Authors:  Rupa Kanapathipillai; Ana Maria Henao Restrepo; Patricia Fast; David Wood; Christopher Dye; Marie-Paule Kieny; Vasee Moorthy
Journal:  N Engl J Med       Date:  2014-10-07       Impact factor: 91.245

8.  The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola.

Authors: 
Journal:  BMJ       Date:  2015-07-27

9.  Will Ebola change the game? Ten essential reforms before the next pandemic. The report of the Harvard-LSHTM Independent Panel on the Global Response to Ebola.

Authors:  Suerie Moon; Devi Sridhar; Muhammad A Pate; Ashish K Jha; Chelsea Clinton; Sophie Delaunay; Valnora Edwin; Mosoka Fallah; David P Fidler; Laurie Garrett; Eric Goosby; Lawrence O Gostin; David L Heymann; Kelley Lee; Gabriel M Leung; J Stephen Morrison; Jorge Saavedra; Marcel Tanner; Jennifer A Leigh; Benjamin Hawkins; Liana R Woskie; Peter Piot
Journal:  Lancet       Date:  2015-11-23       Impact factor: 79.321

  9 in total
  19 in total

1.  Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.

Authors:  Nicholas J Lennemann; Andrew S Herbert; Rachel Brouillette; Bethany Rhein; Russell A Bakken; Katherine J Perschbacher; Ashley L Cooney; Catherine L Miller-Hunt; Patrick Ten Eyck; Julia Biggins; Gene Olinger; John M Dye; Wendy Maury
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

Review 2.  Insights from clinical research completed during the west Africa Ebola virus disease epidemic.

Authors:  Amanda Rojek; Peter Horby; Jake Dunning
Journal:  Lancet Infect Dis       Date:  2017-04-28       Impact factor: 25.071

Review 3.  Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.

Authors:  David S Fedson
Journal:  Ann Transl Med       Date:  2016-11

4.  Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.

Authors:  Scott A Halperin; Jose R Arribas; Richard Rupp; Charles P Andrews; Laurence Chu; Rituparna Das; Jakub K Simon; Matthew T Onorato; Kenneth Liu; Jason Martin; Frans A Helmond
Journal:  J Infect Dis       Date:  2017-06-15       Impact factor: 5.226

5.  The Role of Animal Research in Pandemic Responses.

Authors:  Jacqueline K Brockhurst; Jason S Villano
Journal:  Comp Med       Date:  2021-10-05       Impact factor: 0.982

Review 6.  Considerations for use of Ebola vaccine during an emergency response.

Authors:  Jenny A Walldorf; Emily A Cloessner; Terri B Hyde; Adam MacNeil
Journal:  Vaccine       Date:  2017-09-07       Impact factor: 3.641

7.  The COVID-19 crisis as an opportunity to strengthen global regulatory coordination for sustained enhanced access to diagnostics and therapeutics.

Authors:  Uttara Soumyanarayanan; Mimi Choong; James Leong; Murray M Lumpkin; Guido Rasi; John H Skerritt; Silke Vogel; John C W Lim
Journal:  Clin Transl Sci       Date:  2021-01-21       Impact factor: 4.689

Review 8.  Increasing efficiency in vaccine Production: A primer for change.

Authors:  Ole Kristian Aars; Michael Clark; Nina Schwalbe
Journal:  Vaccine X       Date:  2021-06-16

9.  Vaccinology in the twenty-first century.

Authors:  Alan D T Barrett
Journal:  NPJ Vaccines       Date:  2016-07-28       Impact factor: 7.344

10.  Herd Immunity to Ebolaviruses Is Not a Realistic Target for Current Vaccination Strategies.

Authors:  Stuart G Masterson; Leslie Lobel; Miles W Carroll; Mark N Wass; Martin Michaelis
Journal:  Front Immunol       Date:  2018-05-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.